About the Company
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CYCCP News
CYCC Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s lead product includes ...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
The R&D tax credit has been an important source of non-dilutive capital supporting Cyclacel’s programs. We appreciate this governmental support as we evaluate potential precision medicine approaches ...
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
Cyclacel Pharmaceuticals, Inc. (CYCCP)
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
Cyclacel Pharmaceuticals Inc CYCC
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cyclacel Pharmaceuticals, Inc. (CYCC)
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel ...
Cyclacel Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Cyclacel Pharmaceuticals Inc
Not all exchange-traded funds are created equal. These five-star funds are some of the cream of the ETF crop. Investing can help you reach the $1 million mark if you start early, stay in the ...
Loading the latest forecasts...